By simultaneously reducing CCR2 expression and MDSC populations, Roscovitine disrupts critical pathways involved in MDSC-mediated immune suppression, thereby promoting enhanced anti-tumor immunity when used in combination with ICB. The gene discussed is CCR2; the disease is neoplasm.